CN Patent

CN107089985B — 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物

Assigned to SmithKline Beecham Ltd · Expires 2019-06-07 · 7y expired

What this patent protects

本申请中描述的是吡咯并{2,3‑d}嘧啶衍生物、它们作为詹纳斯激酶(JAK)抑制剂的用途以及包含它们的药物组合物。

USPTO Abstract

本申请中描述的是吡咯并{2,3‑d}嘧啶衍生物、它们作为詹纳斯激酶(JAK)抑制剂的用途以及包含它们的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN107089985B
Jurisdiction
CN
Classification
—
Expires
2019-06-07
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.